Bharat Coking Coal Limited has implemented price increases ranging from 0.1% to 14% on selected raw coking coal grades for the non-regulated sector. The subsidiary of Coal India Limited enacted this adjustment to correct inter-grade price differentials and better reflect operational costs.

Coking Coal Price Revision Details

The adjustment applies specifically to buyers outside regulated sectors and addresses uneven price structures across various coal types. Affected categories include specific steel grades, direct feed coal, and multiple washery grades.

• Price adjustments range between 0.1% and 14% for selected raw coking coal grades.
• Affected sectors include steel grades I and II and direct feed coal.
• Washery grades impacted span PCC Washery grades W-II through W-VI and HVMC Washery grades W-I through W-VI.
• Operations primarily center around Jharkhand and West Bengal within the Jharia Coalfield.

Concurrently, the Supreme Court of India directed the Union government to establish an expert committee within two weeks on October 8, 2026. This panel will investigate the necessity of providing statutory backing to pharmaceutical marketing regulations following petitions from groups like the Federation of Medical and Sales Representatives’ Associations of India.

Supreme Court Focus on Healthcare Pricing

The judiciary has also challenged the government regarding the limited scope of drug price regulation. Justices questioned why trade margin caps focus primarily on cancer medications instead of encompassing the entire pharmaceutical ecosystem.

• The expert committee must submit recommendations to the Centre within two months of its first meeting.
• The Union government must file a compliance affidavit, with the court scheduled to revisit the matter on January 29, 2027.
• Approximately 82% of medicines remain outside the scheduled category under the Drug Price Control Order of 2013.
• The court highlighted extreme price disparities, including a saline drip line with an MRP of ₹270 and a cardiac stent priced to retailers at ₹5,000 with an MRP of ₹25,000.

While the government argued that excessive intervention could disrupt market dynamics and reduce availability, the court remains focused on balancing public health interests. The broader pricing matter is posted for further consideration on October 27, as regulatory oversight tightens across both energy and healthcare sectors.